to the patient if the prescription is not issued timely must be documented in the medical patient’s record.” E. Section 44531650(D) of the 1976 Code is amended by adding an appropriately numbered item to read: a practitioner in a prescription report provided in accordance “( ) with Section 44531655.” F. Section 44531680(E) of the 1976 Code, as last amended by Act 91 of 2017, is further amended to read: Except as provided in Section 44531640(C)(1), nothing in “(E) this chapter requires a pharmacist to obtain information about a patient from the prescription monitoring program. A practitioner or authorized delegate of a practitioner who knowingly fails to review a controlled substance prescription history, as maintained patient’s in the prescription monitoring program, or a practitioner who knowingly fails to consult with his authorized delegate regarding a controlled substance prescription history before issuing a patient’s prescription for a Schedule II targeted controlled substance, as required by this article, must be reported to his respective board for disciplinary action.” SECTION 4. Section 4047965(A), as last amended by Act 28 of 2013, is further amended by adding an appropriately numbered item at the end to read: notwithstanding item (6), if a patient is being treated by a “( ) facility that primarily engages in the treatment of pain by prescribing narcotic medications and advertises in any medium for any type of pain management services, and the therapeutic use of a targeted controlled substance will or is expected to exceed a period of thirty days, the physician assistant must personally consult with the supervising physician prior to prescribing a targeted controlled substance. When a targeted controlled substance prescribed in accordance with this item is continuously prescribed to the same patient, the physician assistant shall consult with the supervising physician at least once every ninety days to verify that the prescription remains medically appropriate for the patient. For purposes of this item, a controlled means a ‘targeted substance’ Schedule II or Schedule III controlled substance.”
to the patient if the prescription is not issued timely must be documented in the patient’s medical record.” E. Section 44531650(D) of the 1976 Code is amended by adding an appropriately numbered item to read: “( ) a practitioner in a prescription report provided in accordance with Section 44531655.” F. Section 44531680(E) of the 1976 Code, as last amended by Act 91 of 2017, is further amended to read: “(E) Except as provided in Section 44531640(C)(1), nothing in this chapter requires a pharmacist to obtain information about a patient from the prescription monitoring program. A practitioner or authorized delegate of a practitioner who knowingly fails to review a patient’s controlled substance prescription history, as maintained in the prescription monitoring program, or a practitioner who knowingly fails to consult with his authorized delegate regarding a patient’s controlled substance prescription history before issuing a prescription for a Schedule II targeted controlled substance, as required by this article, must be reported to his respective board for disciplinary action.” SECTION 4. Section 4047965(A), as last amended by Act 28 of 2013, is further amended by adding an appropriately numbered item at the end to read: “( ) notwithstanding item (6), if a patient is being treated by a facility that primarily engages in the treatment of pain by prescribing narcotic medications and advertises in any medium for any type of pain management services, and the therapeutic use of a targeted controlled substance will or is expected to exceed a period of thirty days, the physician assistant must personally consult with the supervising physician prior to prescribing a targeted controlled substance. When a targeted controlled substance prescribed in accordance with this item is continuously prescribed to the same patient, the physician assistant shall consult with the supervising physician at least once every ninety days to verify that the prescription remains medically appropriate for the patient. For purposes of this item, a ‘targeted controlled substance’ means a Schedule II or Schedule III controlled substance.”
918_20180403.docx